SALARIUS PHARMACEUTICALS SLRX 深 沪
已收盘 08-01 16:00:00 美东时间
0.63
+0.031
+5.12%
华盛通- 最 高0.70
- 今 开0.6683
- 成交量 406.88万股
- 最 低 0.5876
- 昨 收 0.5993
- 总市值 90.80万
- 52周最高 7.20
- 市盈率 静 --
- 换手率 282.32%
- 52周最低 0.4519
- 委 比 98.53%
- 总股本 144.12万
- 历史最高 2963.00
- 量 比 0.18
- 振 幅 18.76%
- 历史最低 0.4519
- 每 手 1
- 风险率 1.48%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Why Celestica Shares Are Trading Higher By Around 12%; Here Are 20 Stocks Moving Premarket
Shares of Celestica Inc. (NYSE:CLS) rose sharply in pre-market trading after th...
07-29 18:46
Salarius Pharmaceuticals Modifies Security Holders’ Rights
Salarius Pharmaceuticals ( ($SLRX) ) has provided an announcement. Salarius Pha...
07-22 10:02
Salarius Pharmaceuticals Granted Nasdaq Compliance Extension
Salarius Pharmaceuticals ( ($SLRX) ) has issued an announcement. On July 10, 20...
07-14 20:59
Salarius Pharmaceuticals Granted Additional Extension to Regain Compliance with Nasdaq’s Stockholders’ Equity Standard
<p><strong>Salarius Pharmaceuticals</strong> (Nasdaq: SLRX) has been granted an additional extension until late July 2025 to regain compliance with Nasdaq's $2.5 million stockholders' equity requirement, and until early August 2025 to meet the $1.00 minimum bid price requirement for continued listing. Salarius is merging with Decoy Therapeutics, a biopharmaceutical company focused on peptide conjugate therapeutics, to form a new company named Dec...
07-14 12:30
Salarius Pharmaceuticals Announces Two Animal Studies Recently Published In Journals Demonstrating Role Of LSD1
Salarius Pharmaceuticals, Inc. (NASDAQ:SLRX) (Salarius or the Company) announces that two animal studies recently published in peer-reviewed journals provide additional insight into the role of inhibiting
07-09 20:31
Salarius Pharmaceuticals’ Seclidemstat Demonstrates Supporting Role in Inhibiting Validated Oncology Target LSD1 in Two Recently Published Studies
<p><p align="center"><em>Salarius Pharmaceuticals is advancing a Phase 1/2 clinical study for seclidemstat targeting MDS and CMML, with updates expected this year, and progressing its merger with Decoy Therapeutics to form a new company focused on peptide conjugate therapeutics.</em></p>
07-09 12:30
Salarius Pharmaceuticals Approves Reverse Stock Split
Salarius Pharmaceuticals ( ($SLRX) ) has issued an announcement. On July 8, 202...
07-09 00:29
What's Going On With Salarius Pharmaceuticals Shares Today?
Salarius Pharmaceuticals Inc. (NASDAQ: SLRX) shares are up Tuesday following news that the company received a conditional extension from the Nasdaq Stock Market to regain compliance with listing standards.
06-18 03:08
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Gainers Acurx Pharmaceuticals (NASDAQ:ACXP) stock moved upwards by 235.5% to $...
06-17 20:08
Why Lennar Shares Are Trading Higher; Here Are 20 Stocks Moving Premarket
Shares of Lennar Corporation (NYSE:LEN) rose sharply in today's pre-market trad...
06-17 17:51
